Ribosomal protein L7a pseudogene 32 (RPL7AP32)

Ribosomal protein L7a pseudogene 32 (RPL7AP32) is one of several processed pseudogenes derived from the gene encoding ribosomal protein L7a, a structural protein component of the eukaryotic 60S ribosomal large subunit[2][4][6][7]. Pseudogenes like RPL7AP32 do not encode functional proteins, lack regulatory regions needed for expression, and are usually transcriptionally inactive in normal cells[7]. The existence of pseudogenes in the genome is common, especially for ribosomal protein genes, and they typically arise through retrotransposition or DNA duplication events. Functional (protein-coding) homologs such as RPL7A are involved in ribosome assembly and protein synthesis, but the pseudogene variant RPL7AP32 is not associated with biological functions or disease roles[2][7]. The term "ribosomal protein L7a pseudogene 32" is accurate for a pseudogene, but it is not correct to treat this entity as a therapeutic target, receptor, enzyme, or gene relevant to drug development[4][6]. As a pseudogene, RPL7AP32 does not participate in regulated cellular pathways and has no known role in normal or disease physiology. All related clinical and functional information instead maps to the RPL7A gene, not to pseudogenes such as RPL7AP32[2][7]. RPL7AP32 is a genomic processed pseudogene originating from the ribosomal protein L7a gene. It is not a protein, therapeutic target, or receptor; there are no drugs, mechanisms, biomarkers, nor disease associations informative for this pseudogene. The entry is best classified as non-functional or "incorrect" for target-based pharmacological studies.

Other names

RPL7A_8_583RPL7AP32ribosomal protein L7a pseudogene 32